Medication Discovery Using Rat Models of Relapse Tender, USA - 97231691

Procurement Summary

Country : USA

Summary : Medication Discovery Using Rat Models of Relapse

Deadline : 01 Apr 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 97231691

Document Ref. No. : 75N95024R00011

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Purchaser : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Contracting Office Address : Bethesda, MD 20892
Primary Point of Contact : Llakim Dubroff
llakim.dubroff@nih.gov
Phone Number 3014436677

Secondary Point of Contact : Tracy Cain
tracy.cain@nih.gov
Phone Number 3014436677
USA
Email :llakim.dubroff@nih.gov

Tender Details

Description

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified organizations (NAICS Code 541715) having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for other drug dependence disorders, using drug self-administration reinstatement models.

The object of this contract is to determine the in vivo efficacy of novel compounds in animal models of relapse using cocaine, nicotine, methamphetamine, or opioids. This includes the following tests in animals trained to self-administer cocaine (for example): (1) the ability of test compound to block footshock or other stress-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with the training drug) to reinstate responding for the training drug (cocaine, nicotine, methamphetamine, or an opioid) after a period of extinction.

An integral part of this work is to develop methods and to design and implement protocols for the evaluation of test compounds. A number of laboratories have used some of the methodologies described in the literature. While recognizing the need for methods development, NIDA anticipates that by Option Period 1, if Options are exercised, the majority of the Contractor-s efforts will be devoted to test compound evaluations. The Contractor shall identify and acquire standard compounds that merit the aforementioned types of evaluation. In addition, if NIDA exercises specific contract options, this contract shall support follow-up rodent pharmacology studies of compounds identified as promising potential drug-dependence treatment agents including through the use of drug selfadministration studies. The details of these latter studies cannot be specified before contract award;...
Active Contract Opportunity Notice ID 75N95024R00011 Related Notice 75N95024R00011 Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier NATIONAL INSTITUTES OF HEALTH Office NATIONAL INSTITUTES OF HEALTH NIDA
General Information
Contract Opportunity Type: Solicitation (Original)
All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Feb 16, 2024 05:06 pm EST
Original Date Offers Due: Apr 01, 2024 03:00 pm EDT
Inactive Policy: 15 days after date offers due
Original Inactive Date: Apr 16, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code: AN11 - Health R&D Services; Health care services; Basic Research
NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance: Rockville, MD USA

Documents

 Tender Notice

RFP-75N95024R00011-002.pdf